Amgen Inc (AMGN) Stock Price

290.52 ▲ +11.31 (+4.05%)
Open: 280.01 Vol: 3.5M Day's range: 278.98 - 293.98 Jul 01, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
AMGN Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 290.73▼ 290.53▼ 290.68▼ 281.26▲ 288.51▲
MA10 290.83▼ 290.79▼ 286.39▲ 282.53▲ 282.19▲
MA20 290.76▼ 285.30▲ 282.49▲ 287.13▲ 291.65▼
MA50 290.72▼ 281.76▲ 280.90▲ 281.21▲ 298.48▼
MA100 286.54▲ 281.61▲ 287.26▲ 292.56▼ 291.86▼
MA200 282.44▲ 287.71▲ 285.25▲ 294.21▼ 264.96▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.086▼ 0.377▲ 1.341▲ -0.750▼ 0.697▲
RSI 48.659▼ 68.442▲ 69.101▲ 56.168▲ 50.761▲
STOCH 34.794     64.104     83.668▲ 43.558     68.515    
WILL %R -77.698▼ -20.795▲ -19.790▲ -28.332     -45.697    
CCI -120.048▼ 45.364     78.924     14.365     38.317    
Latest Filters Detected On AMGN
▲ RSI&VOL $AMGN RSI Cross Up and Volume Set Alert
RSI $AMGN RSI(14) Crossed Above 50 Set Alert
MA $AMGN Price Crossed Above MA(50) Set Alert
MA $AMGN Price Crossed Above MA(26) Set Alert
MA $AMGN Price Crossed Above MA(13) Set Alert
MA $AMGN Price Crossed Above MA(7) Set Alert
Amgen Inc News
Amgen, Zai Lab succeed in gastric cancer study
Monday, June 30, 2025 08:00 AM
Amgen (NASDAQ:AMGN) and Zai Lab (NASDAQ:ZLAB) said on Monday that a late-stage trial testing the combination of bemarituzumab and chemotherapy for treating gastric cancer has successfully met its main ...
2 Dividend Stocks to Buy on the Dip and Hold Forever
Monday, June 30, 2025 02:04 AM
Over the past year, Apple (NASDAQ: AAPL) and Amgen (NASDAQ: AMGN), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds. Apple is ...
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
Monday, June 30, 2025 02:00 AM
THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met ...
AMGN historical stock data
date open high low close volume
01/07/25 280.01 293.98 278.98 290.52 3,502,984
30/06/25 278.85 280.04 276.58 279.21 2,963,945
27/06/25 278.57 281.32 275.70 277.13 2,894,455
26/06/25 280.00 286.17 277.75 279.11 2,998,396
25/06/25 275.80 280.54 273.13 280.35 2,740,255
24/06/25 273.13 280.01 269.01 277.49 3,687,106
23/06/25 290.075 290.66 267.83 272.44 5,764,884
20/06/25 292.17 294.55 288.54 289.33 6,801,395
18/06/25 290.79 291.87 286.60 289.63 2,026,814
17/06/25 294.41 295.80 289.625 290.05 2,515,461
Quote Details
52wk Low:253.30
52wk High:346.85
Vol:3.5M
Avg Vol(3m):42M
1Y Chng:-13.45%
1M Chng:+5.32%
Add to Watch List
More Information
Market Cap. 149.01B